NCT00505661 · ADVERSE EVENTS

Adverse events

Letrozole in Patients With Ovarian Tumors · Source last updated 2012-04-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame: 4 years and 4 months
Other-event reporting threshold: 5%

Participants affected / participants at risk, as reported
Safety group	Serious events	Other events	Deaths
Letrozole 2.5 mg by mouth (PO) daily	0 / 16	4 / 16	Not reported / Not reported

Group identifiers: EG000: Letrozole

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

Other reported adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

assessment Type
SYSTEMATIC_ASSESSMENT
organ System
General disorders
source Vocabulary
CTCAE (2.0)
stats
group Id
EG000
num Affected
4
num At Risk
16
num Events
4
term
Fatigue

Complete source fields

event Groups

description
2.5 mg by mouth (PO) daily
id
EG000
other Num Affected
4
other Num At Risk
16
serious Num Affected
0
serious Num At Risk
16
title
Letrozole

frequency Threshold

other Events

assessment Type
SYSTEMATIC_ASSESSMENT
organ System
General disorders
source Vocabulary
CTCAE (2.0)
stats
group Id
EG000
num Affected
4
num At Risk
16
num Events
4
term
Fatigue

time Frame

4 years and 4 months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice